Products and Services

Aptar Pharma’s LuerVax single-use nasal vaccine delivery device is now CE marked, the company announced. An optional accessory that allows for division of the vaccine so that half of the dose can be sprayed into… Read more . . .

Aptar Pharma has announced the addition of molding capabilities to its OINDP manufacturing facility in Mumbai, India, which was opened in 2023. Products produced at the plant include MDI valves, breath-actuated inhalers, and nasal delivery devices.… Read more . . .

CDMO Bespak, which recently said that it had partnered with Upperton to offer nasal drug/device development and manufacturing and launched a new soft mist intranasal delivery device, has announced that it will now offer access… Read more . . .

CDMO Bespak, which recently announced a collaboration with Upperton to offer complete nasal drug/device development and manufacturing services, has now announced the launch of a new soft mist nasal delivery device called NasaDose Ultra Soft Unit… Read more . . .

Aptar Pharma has announced that its Orbital high-payload dry powder inhaler will be key to a Macquarie University research project titled “Unlocking the Potential of Dry Powder Carriers for Biologic Applications” which is funded by a… Read more . . .

OINDP specialist CDMOs Bespak and Upperton have announced a new strategic collaboration that will offer Upperton nasal drug development services including formulation and clinical manufacturing capability, in conjunction with Bespak nasal delivery devices. Upperton introduced… Read more . . .

Drug delivery specialist Zeteo Biomedical has announced the availability of its first device for delivery to the lung, the AriesMR DPI, which the company describes as “a reloadable active dry powder inhaler designed for controlled… Read more . . .

Aptar Pharma will provide nasal delivery technology for a project led by Massachusetts General Hospital Assistant Professor Alice Stanton to develop a platform designed to improve development of therapies intended for nose-to-brain delivery. The company… Read more . . .

Aptar Pharma has announced a deal with French biotech Aceso Therapeutics related to development of Aceso’s ACT-101 antisense oligonucleotide for the treatment of cystic fibrosis. According to Aptar, its subsidiary Nanopharm will provide development services… Read more . . .